Two hundred samples were taken from children under five with respiratory infections. Of these, 13 isolates contained
bocavirus DNA, and the prevalence of this virus was obtained as 6.5% (
Table 2). The 13 samples positive for
bocavirus were tested for genotype by real-time PCR, revealing that they were all
bocavirus type one. Of 200 studied patients, 116 (58%) were male, and 84 (42%) were female. Of 116 males, 10 (8.62%) were positive, and 106 (91.38%) were negative for
bocavirus. Out of 84 females, 3 (3.57%) were positive, and 81 (96.43%) were negative for
bocavirus. We found no significant correlation between the prevalence of
bocavirus and gender (P = 0.345).
Various clinical signs and symptoms are shown in
Table 2, and the most common were cough (87.5%), runny nose (74.5%), and fever (64.5%). Of 13 positive cases, the cough was present in 13 cases (100%), fever in 12 cases (92.3%), and wheezing in 11 cases (84.6%). Furthermore, 10 (76.9%), 5 (38.5%), 4 (30.8%), 4 (30.8%), and 1 (7%) patients had runny nose, diarrhea, otitis media, nausea and vomiting, and sore throat, respectively. There was a significant relationship between
bocavirus positivity and symptoms, such as fever, otitis media, diarrhea, as well as nausea, and vomiting.
The mean age of cases with
bocavirus infection was 18.92 months, and there was a relationship between age and the prevalence of
bocavirus so that there were more infants under 10 months among the positive cases (
Table 3). The prevalence of
bocavirus is shown in
Table 3. Among infants aged 11 - 20 months, 7 cases (53.8%) were positive, and 38 patients (20.3%) were negative for
bocavirus. It was observed that 3 (23.1%) and 24 (12.8%) of the infants under 10 months were positive and negative for
bocavirus, respectively. In other age groups, only one case was detected. No positive case was detected among children aged 31 - 40 months. The full spectrum of health conditions associated with HBoV needs to be further assessed. However, similar to other respiratory pathogens, it could cause upper and lower respiratory tract infections. This study did not reveal any complications in follow-up, and no death was reported.